Therapeutic advances in the treatment of multiple myeloma have significantly improved remission duration and overall survival (OS). These strategies have included the use of immunotherapy (interferon), novel agents (bortezomib, thalidomide, and lenalidomide), corticosteroids, and chemotherapy. While novel agents have had a major impact on response rates with initial therapy, most patients with multiple myeloma will eventually relapse. In the setting of minimal residual disease following standard dose or high-dose therapy, a number of different 'maintenance' strategies have emerged to prolong the duration of initial or subsequent remissions. The impact of these strategies on OS and event-free survival (EFS) is critically important, as the use of ineffective maintenance therapy adds the burden of additional cost, morbidity, and may reduce quality of life. Truly successful maintenance therapy will be effective in the setting of minimal residual disease, and will improve not only EFS, but also OS. This review summarizes the currently available data in the maintenance setting for multiple myeloma, and will discuss potential future trials to further address this important issue.
Introduction
Multiple myeloma (MM) is a malignant plasma cell disorder that has historically been treated with corticosteroids, alkylating agents, high-dose chemotherapy and autologous transplant, and more recently with novel agents such as thalidomide, lenalidomide, and bortezomib. Standard doses of conventional chemotherapy can achieve response rates of 50-60% with a median survival of 2-2.5 years.
1 High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) significantly improves response rates, event-free survival (EFS), and overall survival (OS) compared with standard dose chemotherapy, but is not curative. 2, 3 A recent publication suggests that patients treated as part of the total therapy 1 program achieved long-term, disease-free survival; however, whether this is truly a 'cure' remains unclear. 4 Based upon the inevitability of relapse, maintenance therapies have been explored to prolong duration of remission. This is of particular interest as biologic-based therapies directed at targeting the bone marrow microenvironment may be more effective in the setting of low tumor burden or minimal residual disease. Clinical trials in the maintenance setting have included the use of alpha-interferon (a-IFN), glucocorticoids, thalidomide, or combinations of these agents. Recent biologic-based strategies in the maintenance setting have the advantage of targeting the stromal/tumor cell interaction, thus interrupting the vicious cycle of autocrine and paracrine cytokine secretion and interrupting cell adhesion-mediated drug resistance. 5 The definition of maintenance therapy for myeloma is extended drug therapy, administered after achieving a remission or a plateau phase, or in this case when disease is at its minimum. Defining the dose, schedule, and the clinical scenario for maintenance therapy is an important starting point. The ideal maintenance therapy is easily delivered (oral) and, if given intravenously, has a schedule that is convenient for patients. The toxicity from the maintenance agent should be modest and its use should improve progression-free survival (PFS). Ideally, the use of the maintenance treatment should not only improve PFS but also improve OS compared with retreatment at the time of relapse. Such goals for maintenance therapy allow clinicians to target populations, agents, and schedules that are patient friendly and demonstrate efficacy.
Interferon
One of the first reports evaluating the role of IFN in myeloma came from Mellsted et al., who demonstrated a complete response in two out of his four patients treated with interferon as single-agent induction therapy. 6 Since that initial report, interferon alpha has been evaluated in clinical trials as singleagent induction therapy, induction in combination with chemotherapy, as salvage therapy, and as maintenance therapy in either plateau phase or complete remission with or without transplantation (Table 1) . Response rates following IFN therapy must be put into the context of response criteria, which have migrated towards stricter definition of complete response over the past 20 years.
Interferon maintenance after standard dose chemotherapy in plateau phase Mandelli et al. were the first investigators to evaluate the utility of interferon in the maintenance setting. 7 One hundred and one patients were randomized to interferon a-2b or no treatment following 12 courses of induction chemotherapy. The use of interferon significantly improved the duration of response (26 vs 14 months) with no significant improvement in OS (52 vs 39 months). 7 Interestingly, when the subset of patients who achieved the best response to induction chemotherapy (475% decrease in M-protein from baseline) was evaluated, the improvement in OS seen among the IFN-treated patients did reach significance (P ¼ 0.035), suggesting a benefit for chemotherapy-sensitive disease. Several other studies failed to corroborate these findings and failed to show an improvement in PFS or OS (Table 1) . 8, 9 The Medical Research Council (MRC) enrolled 254 patients to receive IFN 3 MU three times weekly or observation after achieving plateau phase. 10 Of the 284 enrolled patients, 255 (89.7%) achieved plateau phase following induction with ABCM (N ¼ 194) (doxorubicin, BCNU, cyclophosphamide and melphalan) or ABCMP (ABCM þ prednisone) (N ¼ 61). Other regimens used were VAD (vincristine, doxorubicin, dexamethasone), MP (melphalan, prednisone), high-dose melphalan, prednisone plus IFN, or cyclophosphamide weekly. Among those randomized to maintenance or observation, there was no significant difference in OS (42.1 months for IFN vs 34.5 months for observation, P ¼ 0.57), although there was a trend towards longer median relapse-free survival (RFS) among patients receiving IFN compared to observation only (16.9 months vs 12.7 months respectively, P ¼ 0.2). The observation was also noted in several smaller studies (Table 1) . [11] [12] [13] [14] A major factor to be considered when discussing maintenance therapy is the impact chronic therapy will have on future therapies, especially given the incurability of any therapy in this disease. A trial from Alexanian et al. 15 compared dexamethasone 20 mg/m 2 vs IFN 3 MU three times a week for maintenance treatment after melphalan and dexamethasone induction therapy. There was no difference between the two arms with respect to PFS or OS. Upon relapse, the patients were re-treated with the same induction regimen. Those who were treated with IFN maintenance were more likely to achieve a second response compared to those receiving dexamethasone (82 vs 44%). The responses also tended to be longer (median 15 months vs 10 months), but this did not reach statistical significance. Considering the increasing number of available agents for myeloma, the issue of 'running out of agents' is becoming less important, but toxicities from maintenance Maintenance therapy in multiple myeloma R Mihelic et al approaches should be heavily weighed, as they may limit the delivery of future therapy. Meta-analyses on the use of IFN both as maintenance and as part of the induction therapy was reported from the Myeloma Trialists' Collaborative Group. In their analysis where only maintenance trials were pooled, PFS and response duration were improved compared to no maintenance (27 vs 19% at 3 years, Po0.00001). 16 However, OS was poorer for patients receiving IFN as maintenance therapy (P ¼ 0.007). The authors note that in the trials evaluated, the magnitude of benefit of IFN was greatest in smaller trials, with less or no clear benefit from the larger trials. Thus it would appear that the absolute benefit for IFN either in combination with or following standard dose therapy is marginal. In a separate analysis by Ludwig and Fritz, 1615 patients from 13 different trials were evaluated. In their analysis there was only a modest benefit in both PFS and OS for those receiving IFN as maintenance therapy.
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Recommendation: IFN should not routinely be used as maintenance therapy following standard dose therapy due to its lack of clinical benefit.
Level of evidence: I Grade of recommendation: A
Interferon maintenance after high-dose chemotherapy and HSCT
The story for IFN maintenance following high-dose therapy and autologous transplant is a bit more complex, but raises interesting questions about biological benefits of maintenance therapy in the setting of minimal residual disease. One of the first studies to evaluate IFN post-AHSCT was from Attal et al. who piloted its use among patients who achieved plateau phase (35 patients) after VAD or vincristine, cyclophosphamide, melphalan, prednisone (VCMP) followed by high-dose therapy and AHSCT. 18 Interferon was given 3 MU thrice weekly after AHSCT until relapse. Forty three percent (43%) of patients achieved a complete response (CR) after AHSCT and 40% remained in partial response (PR). At 33 months of follow-up post-AHSCT, there was an 85% probability of PFS for those achieving a CR and 24% for those who only achieved a PR after induction therapy and AHSCT. The results of this small study are quite similar to that of single autologous transplant without interferon maintenance.
To date only one randomized trial from Cunningham et al.
19
has been completed using interferon as maintenance therapy post-AHSCT. This study randomized 85 patients either to 3 MU IFN thrice weekly or to observation. Of these 85 patients, 65 were in complete remission at the time of randomization. At a median follow-up of 52 months PFS was significantly longer for the maintenance arm (46 vs 27 months, Po0.025) as was OS (5 vs 14 deaths, P ¼ 0.006). Of interest is the fact that for the 65 patients achieving a CR there was a significant prolongation of remission, and 49% of the patients in CR who received IFN were in remission at four years of follow-up. This supports the claim that those who will benefit the most from maintenance treatment are those with low tumor burden. However, both PFS and OS ceased to be significant with a median follow-up of 77 months due to patients ultimately dying of their disease. 19 In the most recent US Intergroup study S9321, Barlogie and colleagues randomized 899 patients to receive Vincristine, BCNU, Melphalan, Cyclophosphamide, Prednisone (VBMCP) or high-dose chemotherapy (HDT) followed by AHSCT after induction treatment with VAD for four cycles. Responders to VBMCP or HDT were then randomized to IFN maintenance (N ¼ 120) or observation (N ¼ 119). The addition of IFN did not result in a benefit in OS or PFS in this large randomized study. 20 Despite data suggesting that maintenance therapy is associated with a more durable plateau phase and a modest increase in survival, the use of interferon as maintenance remains controversial. Although some show that use of interferon does improve PFS, this does not consistently translate into a survival benefit, and many show no benefit at all. The difficulty in the control arms of these studies went onto further treatment or were allowed to cross over to interferon. Only one study to date showed a benefit in OS and PFS for interferon maintenance, and this study had a high number of patients in CR, further supporting that the best setting for IFN may be in the minimal residual disease status where potentially immunologic mechanisms may be at work. Doses of 2-5 MU three times a week demonstrate some benefit, though they can be difficult to administer due to hematological and non-hematological toxicity.
In view of conflicting data, the true benefit for IFN maintenance remains an area where extensive discussion with patients regarding side effects and potential benefits are needed, with the result that few myeloma patients now receive it. In an area of rapidly increasing treatment options, novel agents, which are easier to administer, have less toxicity and more biologic rationale, outweigh the limited benefits for IFN.
Recommendation: IFN should not routinely be used as maintenance therapy following HDT and HSCT.
Level of evidence: II Grade of recommendation: A
Glucocorticoids
Glucocorticoids have long been the mainstay of therapy for patients with multiple myeloma, with impressive single-agent activity. [21] [22] [23] These drugs work by suppressing the production of cytokines important in myeloma growth and bone disease (interleukin-6, IL-1b), by inducing apoptosis, and by inhibiting Nuclear Factor-kappa B. A single-arm study of patients who achieved stable disease or better following conventional chemotherapy suggested that patients who received prednisone 50 mg thrice weekly and interferon had a longer duration of remission and improved OS. 24 A large randomized SWOG (SWOG No. 9210) trial evaluated the benefit of prednisone maintenance therapy in 125 patients responding to induction therapy with VAD plus prednisone or VAD plus prednisone and quinine. 25 In subjects receiving 50 mg of prednisone every other day PRS (14 versus 5 months) and OS (37 versus 26 months) were significantly longer, when compared to those receiving 10 mg every other day. Therapy was continued until disease progression. The toxicities at these schedules were reported to be modest with only one patient in the high-dose prednisone group who had therapy discontinued early. Although few clinicians will use VAD alone as induction therapy, this study has formed the justification for most trials testing the benefit of maintenance steroids following either highdose therapy or standard therapy for myeloma.
A separate SWOG (SWOG No. 9028) study compared two different maintenance regimens after induction chemotherapy. 26 Patients who responded to VAD chemotherapy were randomized to either prednisone 50 mg three times weekly with interferon 3 MU thrice weekly or interferon alone at the same dose. The combination of IFN þ prednisone was statistically superior to IFN alone in PFS (19 months vs 9 months), but not OS. Median survival from the start of maintenance was improved on both arms (57 months for IFN/P vs 46 months for IFN), and toxicities of this regimen were reported as being well tolerated with no instances of grade 4 toxicities in the IFN-alone arm. Grade 3 or less toxicity was thought to be due to the IFN administration, which included malaise and leukopenia. There is limited randomized trial data evaluating the role of maintenance corticosteroids following AHSCT to date.
Recommendation: The role of single-agent glucocorticoids should not routinely be used as maintenance therapy following standard therapy or high-dose therapy after AHSCT.
Level of evidence: II Grade of recommendation: B
Thalidomide
Interest in thalidomide as a treatment option was first generated when it was noted that bone marrow microvessel density could be correlated with survival among patients with newly diagnosed multiple myeloma. In the initial report from Singhal et al., the response rate for single-agent thalidomide in refractory myeloma was 25%, with several subsequent studies confirming these results. [27] [28] [29] [30] Further studies were then undertaken to explore its use in combination with other agents. In relapsed/ refractory myeloma, response rates increased when thalidomide was combined with corticosteroids. 31, 32 This led to subsequent studies using thalidomide as first-line therapy alone or in combination with other agents. 30, [33] [34] [35] [36] A retrospective matched case-control analysis by Cavo et al. 35 compared VAD vs thalidomide plus dexamethasone (Thal-Dex). Thal-Dex resulted in a significantly higher response rate (52 vs 76%, respectively; Po0.001). Given its promising activity and ease of administration, it was an ideal agent to test in the maintenance setting.
Tolerability
As a prelude to the MRC Myeloma IX trial, which opened in 2003, a pilot study examined thalidomide monotherapy as maintenance in patients post-AHSCT. The main endpoint for this study was toxicity and duration of remission post-AHSCT. The long-term tolerance of thalidomide was assessed at five dose levels: 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg. With a median follow-up of 6 months, 21% (18/84) of patients discontinued thalidomide, seven due to progression of disease and 11 secondary to toxicities (Feyler et al., Blood 2003; 102(11): abstract No. 2558). With early follow-up, the authors concluded that an apparent increase in toxicity-related dropout was seen in doses above 200 mg per day, with only 58% of patients remaining on study drug as compared with 82% in patients taking 200 mg or less. Of interest, only one thrombosis was seen despite lack of prophylactic anti-coagulation. An additional study confirmed the benefit and tolerance of 200 mg a day of thalidomide as a reasonable starting dose for further exploration of maintenance dosing. 37 In another randomized clinical trial, Stewart and colleagues initiated a randomized phase II study to assess tolerability of thalidomide and prednisone combination after AHSCT. Within 60-100 days of transplant, all eligible patients received prednisone 50 mg orally on alternate days and thalidomide starting at either 200 or 400 mg daily. After a median follow-up of 36.8 months, 31% of patients in the 200 mg arm and 69% in the 400 mg arm either dropped out or had a dose reduction due to side effects (primary endpoint). 38 Patients remaining on maintenance therapy after 18 months were 76% in the 200 mg vs 41% in the 400 mg arm. Neuropathy was the most common reason for discontinuation of thalidomide in both treatment groups. Grade 3 or 4 non-hematological toxicities were observed in 36 and 27% of patients in the 400 and 200 mg dose arms, respectively. The occurrence of symptomatic venous thrombotic events was 7.5% for all patients with no difference between the groups. The median PFS post-transplant for both arms combined was 32.3 months. The authors concluded that 200 mg was the recommended dose for a randomized phase III trial comparing thalidomide and prednisone to placebo as maintenance after transplant.
Efficacy
In a retrospective analysis by Brinker et al., 39 a total of 112 patients were evaluated who received maintenance therapy with IFN and thalidomide, or observation, following high-dose chemotherapy and AHSCT. Patients who received thalidomide at any point after transplant had improved median survival (79.6 months) compared to patients who did not (39.6 months). In a multivariate analysis of this patient group taking into account response to transplant, stem cell source, and other factors that may influence outcomes following transplant, the significant predictors for OS were age and use of thalidomide anytime after transplant (P ¼ 0.09). Although this analysis only indirectly addresses maintenance therapy (one half of the thalidomide group were treated as maintenance with the rest receiving thalidomide at the time of relapse), patients who received maintenance thalidomide had an improved OS compared to patients treated with thalidomide at the time of relapse (P ¼ 0.05).
More recently, the randomized thalidomide maintenance trial, IFM 99 02, was published. The IFM 99 02 trial was initiated to assess the impact of thalidomide maintenance on duration of response post AHSCT in patients with zero or one risk factor as defined by the IFM of an elevated beta-2 microglobulin (b2M) or deletion 13 by flourescence in situ hybridization analysis (FISH). Patients with both risk factors were treated on alternative protocols. Seven hundred and eighty patients less than 65 years old were enrolled to receive VAD induction followed by tandem autologous transplant prepared with melphalan (first transplant 140 mg/m 2 ; second transplant 200 mg/m 2 ). Patients with stable disease or better 2 months after the second transplant were randomized to one of three maintenance therapy arms. At the time of final analysis, 593 of the 780 patients were randomized to receive (1) observation, (2) pamidronate 90 mg/month, or (3) thalidomide 100 mg/day þ pamidronate 90 mg/month as maintenance therapy. At approximately 29 month median follow-up from randomization (2 months after the second transplant), patients randomized to thalidomide had improvement in EFS compared to those patients randomized to no treatment or to pamidronate alone (Arm 3 52 vs Arm 1 36 and Arm 2 37%; P ¼ 0.002). 40 In addition, there was a substantial improvement in OS for the patients randomized to receive maintenance thalidomide compared with the other two arms (Arm 3 87 vs Arm 1 77 and Arm 2 74%; P ¼ 0.04). Importantly, the survival after relapse was no different between the three arms, suggesting that maintenance thalidomide does not result in resistant disease. While the population as a whole had an improvement in EFS, RFS, and OS, there were two subsets of patients who did not benefit from maintenance thalidomide. Patients with deletion 13 (as determined by FISH) and patients who had achieved a very good PR, as defined by a 90% reduction in the paraprotein from baseline, derived no improvement in EFS when randomized to maintenance thalidomide. In fact, the lack of benefit for patients with deletion 13 was independent of response. These data further support the ongoing investigation of maintenance thalidomide, but suggest that separate maintenance strategies need to be developed for patients with deletion 13. This study also questions the role of maintenance thalidomide as a single-agent in patients who have achieved a very good PR or better following high-dose therapy.
Barlogie and colleagues recently published their experience with the use of thalidomide as maintenance in combination with dexamethasone and interferon. In this study, patients were treated in a uniform manner of induction chemotherapy followed by tandem transplants after Melphalan 200 mg/m 2 followed by further intensive chemotherapy for four cycles. All patients who had not progressed and could tolerate further therapy received maintenance with interferon 3 million U/m 2 three times a week and four days of pulse dexamethasone three times per month every 3 months for one year and for subsequent years, interferon alone. Patients were randomly assigned the addition of thalidomide or no thalidomide throughout the entire course of treatment. Complete response measured after each phase of treatment was higher in the thalidomide arm, which translated into an improvement in 5-year EFS from 44 to 56% (P ¼ 0.01) in the thalidomide treatment group. But, in contradiction to the IFM study, there was no survival advantage with the addition of thalidomide. This was because the OS after relapse or progression was significantly lower in the thalidomide-treated patients (1.1 years) compared with patients randomized to no thalidomide (2.7 years; P ¼ 0.001). 41 While this study involved the use of more than maintenance thalidomide, it does raise the possibility that the use of thalidomide may be changing the phenotype of the disease, thus impacting the sensitivity and response rate of disease once it relapses. Clearly, further studies are needed to address the overall role of maintenance thalidomide. The second randomization of the BMT Clinical Trials Network (CTN) 0102 comparing maintenance thalidomide and dexamethasone vs observation after tandem transplants will help define the role of thalidomide as maintenance.
Recommendation: Owing to conflicting evidence, thalidomide should not routinely be used as maintenance therapy following standard therapy or high-dose therapy after AHSCT as single-agent or in combination with other agents outside of a clinical trial. For patients who have not achieved a very good PR after tandem AHSCT and who do not have del 13, thalidomide as maintenance should be considered.
Other maintenance strategies
A pilot phase II trial from Chen et al. treated 28 patients with sequential cycling regimens of multiple drugs for 2 years in an 'ALL-like' maintenance approach following autologous transplant. Patients received decadron 20 mg/day for 4 days every 2 weeks for 3 months (months 1,2,3), then oral melphalan 6 mg/ m 2 /day þ prednisone 50 mg/day for 4 days monthly for 2 months (months 4,5), cytoxan 400 mg po weekly þ prednisone 50 mg/ day every other day for 2 months (months 6,7), IFN-a 3MU three times a week for 3 months (months 8,9,10), followed by a 2-month drug holiday. With a follow-up of 44.6 months, 57% had relapsed or progressed with a median time to relapse/progression of 23. 
Future directions
As the list of active non-cytotoxic agents increases, clinicians will be challenged with more decisions regarding the use of maintenance therapy strategies. Bortezomib maintenance is being tested by a number of different groups, both after standard dose therapy and following high-dose therapy and transplant. Low-dose lenalidomide is being tested by the CALGB in a post transplant randomized placebo-controlled maintenance trial. Results of the studies will hopefully guide evidence-based treatment decisions in an area with little data, but need to be directed at improving OS, not just improved responses or PFS. Other agents that may have a role in the maintenance setting represent targeted approaches directed at the bone marrow stroma as well as the tumor cell. An example of such a strategy is the agent Scio-469, an oral p-38 mitogen-activated protein kinase (MAPK) inhibitor, that has been tested using in vitro models and has modest activity either alone or in combination with bortezomib. 42, 43 The control of a number of transcription factors by inhibiting the p-38 MAPK pathway may be most important in the minimal residual disease setting where tumor/ stromal cell interactions are critical to supporting re-growth of the malignant clone. Interrupting this interaction may delay relapse, or prevent re-establishment of the malignant clone, making it a potential agent for use in the maintenance setting.
Another target that may play a role in the maintenance setting is seen in patients with t(4;14). The t(4;14) occurs in a subset (15%) of patients with MM, and results in the ectopic expression of the receptor tyrosine kinase, fibroblast growth factor receptor 3 (FGFR3). Inhibition of activated FGFR3 in MM cells induces apoptosis, validating FGFR3 as a therapeutic target MM. 44 As has been recently reported by the Mayo clinic group and others, the median PFS for patients with t(4;14) following high-dose therapy is 8 months 45 (Terragna et al. Blood (ASH Annual Other agents that target minimal residual disease via noncytotoxic mechanisms include agents such as the FGFR3 inhibitors TKI-258 and PKC-412, the anti-IL-6 antibody CNTO-328, the anti-CD138 antibody, and antibodies directed at CD40, and IGF-1 ( Table 2) . It is in this setting that strategies directed at the stromal cells within the marrow will likely have the greatest benefit.
Conclusion
Current evidence does not support the use of IFN as maintenance therapy owing to its lack of improvement in OS and unacceptable toxicity. The scant data that are available do not justify the recommendation of corticosteroids as maintenance therapy for all patients. Conflicting evidence exists for the use of thalidomide as maintenance treatment. Current data are promising, but further randomized trials are needed to verify its effectiveness and those who will most likely benefit from maintenance thalidomide. More randomized trials are needed in order to make clear recommendations to patients regarding maintenance therapy. In addition to PFS, OS and quality of life measures are needed. Two published guidelines regarding the treatment of myeloma have recently been published, from The Italian Society of Hematology (SIES) and Italian group for Bone Marrow Transplantation (GITMO) (2004) , and the other from the International Myeloma Foundation (2003). Recommendations for maintenance therapy from both these organizations are found in Table 3 . 46, 47 The discovery, development, and validation of targets in myeloma are a rapidly expanding area of clinical investigation. Additionally, immune-based therapies such as vaccines or primed T-cell infusions may be most effective in the minimal residual disease status, and should be tested as well. Understanding myeloma biology has allowed investigators access to new treatment options. Now we must validate these agents and approaches if we are ever able to manage myeloma as a chronic illness, or a potential cure.
